All Updates

All Updates

icon
Filter
Funding
Karius raises USD 100 million in Series C funding to expand Karius Test infectious disease diagnostic tool
Precision Medicine
May 2, 2024
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Product updates
Partnerships
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Precision Medicine

Precision Medicine

May 2, 2024

Karius raises USD 100 million in Series C funding to expand Karius Test infectious disease diagnostic tool

Funding

  • Karius has raised USD 100 million in Series C funding co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare, with participation from Seventure Partners, Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, and Waycross Ventures.

  • The funds are expected to address the demand for its proprietary Karius Test—expanding beyond its current reach of 400 US hospitals—and to facilitate research exploring the wider health implications of Karius' microbial cell-free DNA technology beyond infectious ailments.

  • Karius operates in the life sciences sector, focusing on infectious disease diagnostics through genomic insights. Its Karius Test is a liquid biopsy test that non-invasively detects ~1,000 pathogens from a single blood sample. This test uses advanced genomics and AI to analyze microbial cell-free DNA, providing diagnostic information that enables rapid treatment decisions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.